JMS Co., Ltd. (JP:7702)
:7702
Top Page
JMS Co., Ltd.
(7702)
Select Model
Select Model
Rating:46Neutral
Price Target:
¥422.00
▼(-4.52% Downside)
Action:ReiteratedDate:10/30/25
The overall stock score of 46 for JMS Co., Ltd. is primarily driven by weak financial performance, with significant concerns in profitability and negative free cash flow posing risks. Technical analysis indicates a neutral trend with no strong momentum, while valuation offers a slight positive through a decent dividend yield despite a negative P/E ratio. Investors should remain cautious due to financial challenges.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.
Negative Factors
Negative Free Cash Flow
Negative free cash flow indicates potential issues with capital expenditure management, which could strain financial resources and limit growth opportunities.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.
Read all positive factors
JMS Co., Ltd. (7702) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥10.77B
Dividend Yield3.85%
Average Volume (3M)25.96K
Price to Earnings (P/E)31.5
Beta (1Y)0.65
Revenue Growth0.38%
EPS GrowthN/A
CountryJP
Employees5,283
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)3.52
Shares Outstanding24,733,465
10 Day Avg. Volume29,090
30 Day Avg. Volume25,963
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)0.28
Price to Sales (P/S)0.16
P/FCF Ratio-7.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
JMS Co., Ltd. Business Overview & Revenue Model
Company Description
JMS Co.,Ltd. manufactures, sells, exports, and imports medical devices and pharmaceuticals in Japan and internationally. The company offers infusion and transfusion sets, infusion sets with a needleless access port, disposable needles and syringes...
How the Company Makes Money
JMS Co., Ltd. generates revenue through multiple streams, primarily by selling its precision instruments and components directly to various sectors such as healthcare, manufacturing, and environmental services. The company's revenue model includes...
JMS Co., Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 69.12B | 69.75B | 65.29B | 63.74B | 58.17B | 57.58B |
| Gross Profit | 15.84B | 15.93B | 14.09B | 14.60B | 14.27B | 15.10B |
| EBITDA | 4.20B | 4.79B | 4.08B | 4.38B | 4.59B | 5.64B |
| Net Income | -277.00M | 89.00M | -36.00M | 281.00M | 826.00M | 1.74B |
Balance Sheet | ||||||
| Total Assets | 80.33B | 81.43B | 84.71B | 74.41B | 71.97B | 69.08B |
| Cash, Cash Equivalents and Short-Term Investments | 6.20B | 5.51B | 10.31B | 6.33B | 6.81B | 6.22B |
| Total Debt | 23.36B | 24.55B | 26.92B | 19.75B | 18.71B | 18.50B |
| Total Liabilities | 40.34B | 40.50B | 43.96B | 35.70B | 34.87B | 34.09B |
| Stockholders Equity | 39.91B | 40.84B | 40.57B | 38.53B | 36.96B | 34.84B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.42B | 498.00M | -1.07B | 1.14B | 481.00M |
| Operating Cash Flow | 0.00 | 1.47B | 3.14B | 2.48B | 4.40B | 3.74B |
| Investing Cash Flow | 0.00 | -3.14B | -4.24B | -3.69B | -3.68B | -3.25B |
| Financing Cash Flow | 0.00 | -3.19B | 4.78B | 525.00M | -499.00M | -535.00M |
JMS Co., Ltd. Technical Analysis
Positive
442.00
Price Trends
431.04
Positive
431.39
Positive
428.71
Positive
Market Momentum
1.87
Negative
58.39
Neutral
77.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7702, the sentiment is Positive. The current price of 442 is above the 20-day moving average (MA) of 429.68, above the 50-day MA of 431.04, and above the 200-day MA of 428.71, indicating a bullish trend. The MACD of 1.87 indicates Negative momentum. The RSI at 58.39 is Neutral, neither overbought nor oversold. The STOCH value of 77.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7702.
JMS Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥3.26T | 25.64 | 8.98% | 1.22% | 7.68% | 10.08% | |
68 Neutral | ¥977.19B | 24.33 | 11.64% | 0.82% | 13.53% | -7.39% | |
59 Neutral | ¥1.76T | 38.56 | 11.34% | 1.01% | 0.42% | 34.76% | |
55 Neutral | ¥143.37B | 67.81 | 0.30% | 1.31% | -2.06% | -79.17% | |
54 Neutral | ¥265.11B | 5.59 | 4.38% | 2.03% | 6.04% | 733.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | ¥10.77B | 31.52 | ― | 3.85% | 0.38% | ― |
* Healthcare Sector Average
JP:7702
JMS Co., Ltd.
433.00
16.19
3.88%
JP:4543
Terumo
2,171.00
-650.97
-23.07%
JP:7747
Asahi Intecc Co
3,599.00
1,343.25
59.55%
JP:3593
Hogy Medical Co
6,650.00
2,359.34
54.99%
JP:8086
Nipro
1,634.00
339.39
26.22%
JP:7733
Olympus
1,588.50
-232.09
-12.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.